Vamifeport

Generic Name: Vamifeport

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₁FN_₆O_₂

CAS Number: 2095668-10-1

Unique Ingredient Identifier: FUF66UD0KR

Background: Vamifeport is being investigated for the treatment of beta-thalassemia.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Sickle Cell Disease Treatment Market Size to Surpass USD

The global Sickle Cell Disease Treatment Market, valued at USD 1.73 billion in 2021, is projected to grow to USD 8.75 billion by 2029, with a CAGR of 21.4%. Growth is driven by increasing disease prevalence, effective drug launches, and rising healthcare spending. North America leads due to strong government support and collaborations.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy